Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CFT1946 |
Trade Name | |
Synonyms | CFT-1946|CFT 1946 |
Drug Descriptions |
CFT1946 is a bifunctional degradation activation compound (BiDAC) degrader composed of a ligand that targets the BRAF kinase domain linked to a Cereblon ligand, which potentially induces degradation of mutant BRAF and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2158). |
DrugClasses | BRAF Inhibitor 25 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetuximab + CFT1946 | CFT1946 Cetuximab | 0 | 1 |
CFT1946 | CFT1946 | 2 | 1 |
CFT1946 + Trametinib | CFT1946 Trametinib | 0 | 1 |